Acadia Pharmaceuticals Inc.
Clinical trials sponsored by Acadia Pharmaceuticals Inc., explained in plain language.
-
New hope for dementia psychosis: 52-Week drug trial launches
Disease control ENROLLING_BY_INVITATIONThis study tests a drug called ACP-204 for managing psychosis (hallucinations or delusions) in people with Lewy body dementia. It lasts 52 weeks and includes 126 adults who completed a prior study. The main goal is to check for side effects over the long term.
Phase: PHASE3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Disease control
Last updated May 01, 2026 15:08 UTC
-
New hope for Alzheimer's psychosis: 52-Week safety trial launches
Symptom relief ENROLLING_BY_INVITATIONThis study tests the long-term safety of an experimental drug, ACP-204, for people with Alzheimer's disease who also experience psychosis (hallucinations or delusions). It is an open-label extension, meaning everyone gets the drug, and follows 752 adults aged 55-95 for 52 weeks. …
Phase: PHASE3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Apr 30, 2026 15:52 UTC